Literature DB >> 8457043

Inhaled nitric oxide selectively reverses human hypoxic pulmonary vasoconstriction without causing systemic vasodilation.

C G Frostell1, H Blomqvist, G Hedenstierna, J Lundberg, W M Zapol.   

Abstract

BACKGROUND: Nitric oxide (NO), an endothelium-derived relaxing factor, acts as a local vasodilator. The authors examined the effects of NO on pulmonary and systemic circulation in human volunteers.
METHODS: Nine healthy adults were studied awake while breathing 1) air, 2) 12% O2 in N2, 3) followed by the same mixture of O2 and N2 containing 40 ppm of NO. Pulmonary artery and radial artery pressures were monitored.
RESULTS: The PaO2 decreased from 106 +/- 4 (mean +/- standard error of the mean) while breathing air (21% O2) to 47 +/- 2 mmHg after 6 min of breathing 12% O2. Concomitantly, the pulmonary artery mean pressure (PAP) increased from 14.7 +/- 0.8 mmHg to 19.8 +/- 0.9 mmHg, and the cardiac output (CO) increased from 6.1 +/- 0.4 to 7.7 +/- 0.6 L/min. After adding 40 ppm NO to the inspired gas while maintaining the FIO2 at 0.12, the PAP decreased (P < 0.01, by analysis of variance) to the level when breathing air while the PaO2 and PaCO2 were unchanged. The dilation (or recruitment) of pulmonary vessels produced by inhaling NO during hypoxia was not accompanied by any alteration in the systemic vascular resistance or mean arterial pressure (MAP). The authors also examined the effects of inhaling NO while breathing air. Breathing 40 ppm NO in 21% O2 for 6 min produced no significant changes of PAP, CO, PaO2, MAP, or central venous pressure. Plasma endothelinlike immunoreactivity concentrations did not change either during hypoxia or hypoxia with NO inhalation.
CONCLUSIONS: Inhalation of 40 ppm NO selectively induced pulmonary vasodilation and reversed hypoxic pulmonary vasoconstriction in healthy humans without causing systemic vasodilation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8457043     DOI: 10.1097/00000542-199303000-00005

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  49 in total

1.  Inhaled nitric oxide therapy in adults: European expert recommendations.

Authors:  Peter Germann; Antonio Braschi; Giorgio Della Rocca; Anh Tuan Dinh-Xuan; Konrad Falke; Claes Frostell; Lars E Gustafsson; Philippe Hervé; Philippe Jolliet; Udo Kaisers; Hector Litvan; Duncan J Macrae; Marco Maggiorini; Nandor Marczin; Bernd Mueller; Didier Payen; Marco Ranucci; Dietmar Schranz; Rainer Zimmermann; Roman Ullrich
Journal:  Intensive Care Med       Date:  2005-06-23       Impact factor: 17.440

2.  Intravenous infusion of nitric oxide in experimental pulmonary hypertension: biotransformation and haemodynamics.

Authors:  F Pirrone; M Albertini; S Mazzola; C Pastore; M G Clement; M C Benfatto; G Aldini; M Carini
Journal:  Vet Res Commun       Date:  2007-08       Impact factor: 2.459

Review 3.  Determinants of regional ventilation and blood flow in the lung.

Authors:  Robb W Glenny
Journal:  Intensive Care Med       Date:  2009-11       Impact factor: 17.440

4.  NO news is good news.

Authors:  M Sair; T W Evans
Journal:  Thorax       Date:  1995-04       Impact factor: 9.139

5.  A European survey of the use of inhaled nitric oxide in the ICU. Working Group on Inhaled NO in the ICU of the European Society of Intensive Care Medicine.

Authors:  S Beloucif; D Payen
Journal:  Intensive Care Med       Date:  1998-08       Impact factor: 17.440

Review 6.  NO: COPD and beyond.

Authors:  A T Jones; T W Evans
Journal:  Thorax       Date:  1997-08       Impact factor: 9.139

7.  Nitric oxide (NO) measurement accuracy.

Authors:  M Nishimura; H Imanaka; A Uchiyama; C Tashiro; D Hess; R M Kacmarek
Journal:  J Clin Monit       Date:  1997-07

Review 8.  Pulmonary hypertension in obstructive sleep apnea: is it clinically significant? A critical analysis of the association and pathophysiology.

Authors:  Cyrus Kholdani; Wassim H Fares; Vahid Mohsenin
Journal:  Pulm Circ       Date:  2015-06       Impact factor: 3.017

9.  Methaemoglobin production in normal adults inhaling low concentrations of nitric oxide.

Authors:  J D Young; O Dyar; L Xiong; S Howell
Journal:  Intensive Care Med       Date:  1994-11       Impact factor: 17.440

Review 10.  RhoA/Rho-kinase signaling: a therapeutic target in pulmonary hypertension.

Authors:  Scott A Barman; Shu Zhu; Richard E White
Journal:  Vasc Health Risk Manag       Date:  2009-08-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.